NIH #1R03CA293115-01
Activation of SLFN12 RNase Activity by Dimerization
Expiring Soon
- Amount
- $154K
- Period
- 2024-09-01 → 2026-08-31
- PIs
- 1
- Est. capacity / PI
- ~0 students
Awarded at BROAD INSTITUTE, INC.
Heidi Greulich
Full Professor(heuristic)
Lung Cancer Treatments and Mutations · Pulmonary and Respiratory Medicine
h-index52
i10-index69
Publications213
Citations38,194
Grants
3 total · 1 active
NIH #5F32GM019098-02
MEK1 FUNCION IN CELL GROWTH AND DEVELOPMENT
- Amount
- $38K
- Period
- 1998-12-01 → —
- PIs
- 1
- Est. capacity / PI
- ~0 students
Awarded at HARVARD UNIVERSITY
NIH #1F32GM019098-01
MEK1 FUNCION IN CELL GROWTH AND DEVELOPMENT
- Amount
- $30K
- Period
- 1997-12-19 → —
- PIs
- 1
- Est. capacity / PI
- ~0 students
Awarded at HARVARD UNIVERSITY
Student capacity is a rough estimate from remaining award size, split equally among PIs. Actual funding decisions vary.
Career Trajectory
Research Cluster Map
Direct collaborators. Node size = influence, colour = community, dashed = past collaboration.
Potential Collaborators
Recent Publications
Last 2 years · showing 20 of 23ErbB family receptor dimerization dynamics and dysregulation via long-term single-molecule imaging
Cell · 2026-04-29
Protein language model-based fitness estimates facilitate resistance mutation identification
ChemRxiv · 2026-03-15
Table S4 from Sevabertinib, a Reversible HER2 Inhibitor with Activity in Lung Cancer
2026-01-12
Figure S5 from Sevabertinib, a Reversible HER2 Inhibitor with Activity in Lung Cancer
2026-01-12
Figure S4 from Sevabertinib, a Reversible HER2 Inhibitor with Activity in Lung Cancer
2026-01-12
Figure S6 from Sevabertinib, a Reversible HER2 Inhibitor with Activity in Lung Cancer
2026-01-12
Figure S1 from Sevabertinib, a Reversible HER2 Inhibitor with Activity in Lung Cancer
2026-01-12
Figure S2 from Sevabertinib, a Reversible HER2 Inhibitor with Activity in Lung Cancer
2026-01-12
Figure S8 from Sevabertinib, a Reversible HER2 Inhibitor with Activity in Lung Cancer
2026-01-12
Table S5 from Sevabertinib, a Reversible HER2 Inhibitor with Activity in Lung Cancer
2026-01-12
Data from Sevabertinib, a Reversible HER2 Inhibitor with Activity in Lung Cancer
2026-01-12
Table S1 from Sevabertinib, a Reversible HER2 Inhibitor with Activity in Lung Cancer
2026-01-12
Table S2 from Sevabertinib, a Reversible HER2 Inhibitor with Activity in Lung Cancer
2026-01-12
Table S3 from Sevabertinib, a Reversible HER2 Inhibitor with Activity in Lung Cancer
2026-01-12
Figure S3 from Sevabertinib, a Reversible HER2 Inhibitor with Activity in Lung Cancer
2026-01-12
Figure S7 from Sevabertinib, a Reversible HER2 Inhibitor with Activity in Lung Cancer
2026-01-12
Supplementary Methods 1 from Sevabertinib, a Reversible HER2 Inhibitor with Activity in Lung Cancer
2026-01-12 · 1 citations
Molecular Cancer Therapeutics · 2025-10-22
Sevabertinib, a Reversible HER2 Inhibitor with Activity in Lung Cancer
Cancer Discovery · 2025-10-15 · 14 citations
A Role for RAS in V-CRK Transformation
PubMed · 2025-09-08 · 20 citations